학술논문
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
Document Type
Article
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia February 2020 20(2):78-86
Subject
Language
ISSN
2152-2650